Academic Journals Database
Disseminating quality controlled scientific knowledge

Streptokinase :A novel clot buster

Author(s): Vaishnavi. B, Mohanasrinivasan.V and Subathra Devi.C*

Journal: Journal of Pharmacy Research
ISSN 0974-6943

Volume: 4;
Issue: 10;
Start page: 3784;
Date: 2011;
Original page

Keywords: Myocardial infarction | thrombolytics | streptokinase | plasminogen activator.

The leading cause of death in the world is coronary heart diseases. About 7.1 million deaths were attributed to ischemic heart disease in 2001 out of which 80% werein relatively poor countries. According to World Health Organisation (WHO) cardiovascular disease caused over 18 million deaths in the world in 2005. Of thesedeaths, 8 million (44%) occurred in people under 60 years of age. In the recent years, of the several thrombolytic agents used clinically, streptokinase is prone ofthe most-often employed, particularly of its lower cost when coded to others. However, the choice of thrombolytic agent during therapy is dictated by a numberof factors besides costs, such as the presence of side-effects and their severity, in vivo metabolic survival of the drug (e.g., circulatory clearance rates), fibrinselectivity, immunological reactivity etc. Streptokinase is a non-proteolytic extracellular protein produced by Streptococcus species. It is the best, least expensive,efficient, highly potent plasminogen activator of fibrinolysis and routinely applied in clinical medicine for thrombolytic therapy for the treatment of diversecirculatory disorders. Presently there is about 80- 90% of demand for streptokinase. As per market research 2011 report, Asia, Europe and North America are theleading countries worldwide in manufacturing and supplying streptokinase. This review discusses about properties, applications, effects and commercializationincluding present and future perspectives of streptokinase.
Why do you need a reservation system?      Affiliate Program